Business Context and Reporting Period
This Form 8-K is a current report filed by Ventrus Biosciences, Inc. (not Assembly Biosciences, Inc.) on January 17, 2012. The filing reports corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to director compensation:
- Stock Option Grant: 35,000 shares of common stock granted to the new director.
- Exercise Price: $8.10 per share (closing price on the trading day prior to election).
- Vesting Schedule: Three equal annual installments beginning on the first anniversary of the grant.
Material Changes
The filing details the following changes to the Board of Directors effective January 17, 2012:
- Election of Director: Anthony E. Altig was elected as a director to serve until the 2012 annual meeting of stockholders. He was also elected to the audit committee.
- Resignation of Director: Thomas Rowland resigned as a director. He remains the company's Chief Business Officer.
- Compensation Arrangement: No financial transactions or arrangements other than the standard director compensation program were disclosed between Mr. Altig and the company.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The report is strictly limited to the departure and election of directors.
Key Facts for Investor Verification
- Verify the current status of Thomas Rowland as Chief Business Officer following his resignation from the Board.
- Confirm the vesting schedule and exercise price ($8.10) of the 35,000 options granted to Anthony E. Altig.
- Review the attached press release (Exhibit 99.1) for additional context on the leadership transition.
- Note the discrepancy between the requested company name (Assembly Biosciences) and the actual registrant (Ventrus Biosciences).